Lenacapavir, a twice yearly injection that prevents HIV transmission, was named the breakthrough medicine of 2024. But without US foreign aid dollars, its delivery to millions worldwide is under threat.
Lenacapavir, a twice-yearly injectable drug developed by Gilead Sciences, has been named the 2024 Breakthrough of the Year for its 100% efficacy in preventing HIV transmission. The drug targets the virus's capsid protein, disrupting its replication. Gilead plans to produce 10 million doses by 2026, enough to treat 2.5 million people. The Global Fund and PEPFAR had pledged to procure 2 million doses for high-incidence areas, particularly in sub-Saharan Africa. However, US foreign aid cuts, including a freeze on PEPFAR funding, have jeopardized this plan. Researchers and organizations are now seeking alternative funding from European agencies and other donors to ensure the drug's rollout and continue research into new HIV treatments and combinations. Without sufficient funding, the potential to end the HIV epidemic is at risk.